3.1
Atidarsagene autotemcel (Libmeldy, Orchard Therapeutics), referred to as OTL‑200 in the company submission, is a gene therapy medicinal product that expresses the human arylsulphatase A (ARSA) gene. Ex vivo autologous CD34+ haematopoietic stem and progenitor cells are collected from the person's bone marrow or peripheral blood. These are then transduced with a lentiviral vector, which inserts copies of human ARSA complementary DNA into the cell genome, and transplanted into the person. When successfully engrafted, the genetically modified cells secrete functional ARSA enzyme, which is absorbed by surrounding cells and used to break down or prevent build‑up of harmful sulphatides. The effects of OTL‑200 are potentially lifelong.